

**HS272L161**  
**LOCUS**  
**DEFINITION** Human gene isolated from PAC 272L16, chromosome 1, similar to  
 calcium/calmodulin dependent protein kinases.  
**ACCESSION** AL049688  
**VERSION** AL049688.1 GI:4678721  
**KEYWORDS**  
**SOURCE** Homo sapiens.  
**ORGANISM** Homo sapiens.  
**REFERENCE** Katsuyoshi; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
**AUTHORS** Rhodes, S.  
**TITLE** Direct Submission  
**JOURNAL** Submitted (21-APR-1999) E-mail contact: humquery@sanger.ac.uk  
**COMMENT** This sequence was generated from cDNA clones isolated using  
 sequence from the bacterial clone 272L16 (AL023754) and EST data.  
 The EST sequences listed match this sequence with an identity of at  
 least 95% between the coordinates shown.  
 Further information can be found at  
 http://www.sanger.ac.uk/RRP/Chr1/ Partial, experimentally  
 determined gene.  
 Sanger Centre name: dj272L16.C1.1.  
 Location/Qualifiers  
 1..1738  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /chromosome="1"  
 /map="1q32.1-32.3"  
 /c1..1448  
 /codon\_start=3  
 /product="hypothetical protein"  
 /protein\_id="CAB41259.1"  
 /db\_xref="GI:4678722"  
 /translation="STLEANGKREEDCSWRKQTTNIRKTFINELVSGAFSEVEL  
 VKQLATGKLPALCKIKSPAFROSLNEIAVLAKIKHENIVTLEDIVESTTHYLVM  
 QLVSGGLFDRIPLRGVYTKDASLVTOQVLSAVKYLHENGIVRHDLKPEMLLYLTFE  
 ENKIMTDGFLSKMEQNGIMSTACQTPGVAPEVLAKPKISKAVDCMSIGVITYILL  
 CGVPPEVETESKLPKIKGCVYEPESPDDIISAKOPICHLLEKDPNERVTCKA  
 LSHNTDGTALHREDIVPSVLOIQRNPAKSKHROAPNAAVYVHMRHLMHLSGV  
 RPVENRPPETQASERTSRSSPEITETAPVLDHVALDALPOLCOHGRPTARGCR  
 SLKLVNGSLHSSLSLUPMKGQSLAAGCGCSLMSKSGSKSSCEPTLLAKANK  
 KQNFSEYAVPVNAGSGSHCRAGGTGCLIM"  
 /c1..107  
 /number=1  
 108..236  
 /number=2  
 237..311  
 /number=3  
 312..450  
 /number=4  
 451..574  
 /number=5  
 575..650  
 /number=6  
 651..763  
 /number=7  
 /number=8  
 /note="matches EST A1215131 from clone IMAGE:1925595"  
 764..842  
 /number=9  
 843..930  
 /number=10  
 931..1355  
 /note="matches EST AA351937"  
 1356..1483  
 /number=11  
 1484..1736  
 /note="matches EST R05661 from clone 29500"  
 1737..1738  
 /number=12

BASE COUNT 432 a 491 c 458 g 357 t  
 ORIGIN  
 Alignment Scores:  
 Pred. No.: 2,33e-170 Length: 1738  
 Score: 2513.00 Matches: 476  
 Percent Similarity: 100.00% Conservative: 0  
 Best Local Similarity: 100.00% Mismatches: 0  
 Query Match: 100.00% Indels: 0  
 DB: 9 Gaps: 0  
 US-09-960-643-2 (1-476) x HS272L161 (1-1738)  
 QY 1 MetGlyArgLysGluGluAspAspCysSerSerTrpLysGlyGlnThrThrAnlleArg 20  
 DB 18 ATGGGTGCGAAGAGAGATGACAGTTCCTGGAGAACAGACCAACATCCCG 77  
 QY 21 LysThrPheIlePheMetGluValLeuGlySerGlyAlaPheSerGluValPheLeuVal 40  
 DB 78 AAAAACTTCATTTTATGCAAGTCTGGATCGAGAGCTTTCCTGAGAGTTTTCCTGGTG 137  
 QY 41 LysGlnArgLeuThrGlyLysLeuPheAlaLeuLysCysIleLysLysSerProAlaPhe 60  
 DB 138 AAGCAAGACTGACTGGCAAGCTCTTCTCTGAAGTGCATCAAGAGTCACCTGCCTTC 197  
 QY 61 ArgAspSerLeuGluGluGlnIleAlaValLeuLysLysIleLysHleGluAnlle 80  
 DB 198 CGGACAGCAGCGCTGGAGATGAGATTGCTGTGTGANAAGATCAACATGAAACATT 257  
 QY 81 ValThrLeuGluAspIleLeuSerThrThrBisTrpTrpLeuValMetGlnLeuVal 100  
 DB 258 GTGACCTCGAGGACATCTATGAGACACACCTACTACTCTGCTGCTGCTGCTGCTGCT 317  
 QY 101 SerGlyGlyGluLeuPheAspArgIleLeuGluArgGlyValTrpThrGluLysAspAla 120  
 DB 318 TCTGTGGGGAGCTCTTGACCGGATCTCGGAGGGGGTCTCTACACAGAGAGCATGCC 377  
 QY 121 SerLeuValIleGlnGlnValLeuSerAlaValLysTrpLeuHleGluGlnGlyLeuVal 140  
 DB 378 AGTCTGTGATCCAGCAGGTCTTGTGCGCAGTGAATACCTACATGAGATGGCATCGTC 437  
 QY 141 HisArgAspLeuLysProGluGlnLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeu 160  
 DB 438 CACAGAGACTTAAAGCCCGAAGACCTGCTTACCTTACCTTACCTTACCTTACCTTACCT 497  
 QY 161 MetIleThrAspPheGlyLeuSerLysMetGluGlnAsnGlyIleMetSerThrAlaCys 180  
 DB 498 ATGATCAGTGCATCTTTGGTCTGTCTCAAGATGGAGAGAGAGAGAGAGAGAGAGAGAG 557  
 QY 181 GlyThrProGlyTrpValAlaProGluValLeuAlaGlnLysProTrpSerLysAlaVal 200  
 DB 558 GGGACCCAGGCTAGCTGGCTCCAGAGAGTGTGGCCCGCAAGACCCATACAGCAAGGCTGTG 617  
 QY 201 AspCysTrpSerIleGlyValIleThrTrpIleLeuLeuLysGlyTrpProPheTrp 220  
 DB 618 GATTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 677  
 QY 221 GluThrThrGluSerLysLeuPheGluLysIleLysGluGlyTrpTrpTrpTrpTrpTrp 240  
 DB 678 GAAGAAACGAGGCTTAGAGCTTTTCCGAGAGAGATCAAGAGAGAGAGAGAGAGAGAGAG 737  
 QY 241 ProPheTrpAspPheIleSerGluSerAlaLysAspPheIleCysHleLeuLeuGlyLys 260  
 DB 738 CCATTCTGGGATGACATTTCTGAGTCAGCCAGGACTTTATTTGGCAGCTTCTGTTGAG 797  
 QY 261 AspProAsnGluArgTrpThrCysGluLysAlaLeuSerHisProTrpIleAspGlyAsn 280  
 DB 798 GATCCGAGAGAGGCTGACCTCTGAGAGAGGCTTGAGTCATCCCTGCTGCTGCTGCTGCT 857  
 QY 281 ThrAlaLeuHisArgAspIleTrpProSerValSerLeuGlnIleGlnLysAsnPheAla 300  
 DB 858 ACAGCCCTCCACCCGGGACATCTACCCATCAGTACGCTCCAGTATCAGATCAGATCAGAT 917

Oy 301 LysSerLysTyrPargGlnAlaPheAsnAlaAlaValValHisHisMetArgLysLeu 320  
Db 918 AACAGCAAGTCGAGGCCAAGCCTTCAACGCCAGCAGCTGTGGTGCACCATAGGAGCTA 977  
Oy 321 HisMetAsnLeuHisSerProGlyValArgProGluValGluAsnArgProProGluThr 340  
Db 978 CACATGAACTTGCACAGCCCGGGGTCTCCACAGAGGTGGAGAACAGGCCCTGAAACG 1037  
Oy 341 GlnAlaSerGluThrSerArgProSerProGluIleThrIleThrGluAlaProVal 360  
Db 1038 CAAGCCTCAGAAACCTCTAGACCCAGCTCCCTGAGATCACCATCACCGAGCACCTGTC 1097  
Oy 361 LeuAspHisSerValAlaLeuProAlaLeuThrGlnLeuProCysGlnHisGlyArg 380  
Db 1098 CTGGACACAGTAGCACTCCCTGCCCTGACCCAAATTACCTGCCAGCATGGCGCGG 1157  
Oy 381 ProThrAlaProGlyGlyArgSerLeuAsnCysLeuValAsnGlySerLeuHisIleSer 400  
Db 1158 CCCACTGCCCTGTGGCAGGTCCCTCAACTGCTGGTCAATGGTCCCTCCACATCAGC 1217  
Oy 401 SerSerLeuValProMetHisGlnGlySerLeuAlaLeuGlyProCysGlyCysSer 420  
Db 1218 AGCAGCTGTGGCCCATGCAATCAGGGTCCCTGCCCGCGGCTGTGGCTGCTGCTCC 1277  
Oy 421 SerCysLeuAsnIleGlySerLysGlyLysSerSerTyrCysSerGluProThrLeuLeu 440  
Db 1278 AGCTGCTGAACATTGGGAGCAAGAAAGTCCCTCTCTCTGAGCCACACTCCTC 1337  
Oy 441 LysAlaAsnLysLysGlnAsnPheLysSerGluValMetValProValLysAlaSer 460  
Db 1338 AAAAGGCCCAACAAAAACAGAACTTCAAGTCGGAGGTGATGTTACAGTTAAAGCCAGT 1397  
Oy 461 GlySerSerHisCysAlaGlyGlnThrGlyValCysLeuIleMet 476  
Db 1398 GGCAGCTCCCACTGCTCCGGCAGGGCAGACTGGAGTCTGTCTCATTTATG 1445

KW Human; nootropic; immunosuppressant; cyostatic; gene therapy; cancer;  
 KW Peripheral nervous system; neuropathy; central nervous system; CNS;  
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
 KW anyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;  
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;  
 KW leukaemia.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200153312-A1.  
 XX  
 XX 26-JUL-2001.  
 XX  
 XX 26-DEC-2000; 2000WO-US34263.  
 XX  
 XX 21-JAN-2000; 2000US-0488725.  
 XX  
 XX 25-APR-2000; 2000US-0552317.  
 XX  
 XX 09-JUL-2000; 2000US-0598042.  
 XX  
 XX 19-JUL-2000; 2000US-0620312.  
 XX  
 XX 03-AUG-2000; 2000US-0653450.  
 XX  
 XX 14-SEP-2000; 2000US-0682191.  
 XX  
 XX 19-OCT-2000; 2000US-0693036.  
 XX  
 XX 29-NOV-2000; 2000US-0727344.  
 XX  
 XX (NYSE-) HYSEQ INC.  
 XX  
 XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Olan XB, Ren P, Wang D;  
 XX Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;  
 XX Zhao QA, Zhou P, Goodrich R, Dimahec RT;  
 XX  
 XX WPI; 2001-442253/47.  
 XX  
 XX N-PSDB; AAI60703.  
 XX  
 XX Novel nucleic acids and polypeptides, useful for treating disorders  
 XX such as central nervous system injuries -  
 XX  
 XX Example 2; SEQ ID NO 6478; 10078pp; English.  
 XX  
 XX The invention relates to human nucleic acids (AAI57798-AAI61369) and  
 XX the encoded polypeptides (AAI58642-AAI62213) with nootropic,  
 XX immunosuppressant and cyostatic activity. The polynucleotides are useful  
 XX in gene therapy. A composition containing a polypeptide or polynucleotide  
 XX of the invention may be used to treat diseases of the peripheral nervous  
 XX system, such as peripheral nervous injuries, peripheral neuropathy and  
 XX localised neuropathies and central nervous system diseases, such as  
 XX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
 XX lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
 XX utilisation of the activities such as: immune system suppression,  
 XX Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic  
 XX and thrombolytic activity, cancer diagnosis and therapy, drug screening,  
 XX assays for receptor activity, arthritis and inflammation, leukaemias and  
 XX C.N.S disorders.  
 XX Note: The sequence data for this patent did not form part of the printed  
 XX specification.  
 XX  
 XX Sequence 497 AA;  
 XX  
 XX Query Match 100.0%; Score 2513; DB 22; Length 497;  
 XX Best Local Similarity 100.0%; Pred. No. 5,1e-220;  
 XX Matches 476; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX  
 XX 1 MGRKEEDDCSSWKKQTTNIRKTFIFMEVLGSGAFSEVELVKQRLTKLPALKCKKSPAF 60  
 XX DB 22 MGRKEEDDCSSWKKQTTNIRKTFIFMEVLGSGAFSEVELVKQRLTKLPALKCKKSPAF 81  
 XX OY 61 RDSLENEIAVLAKIKKENIVTLEDIYESTHYLYVMOLVSGGELFDRLERGVYTEKA 120  
 XX DB 82 RDSLENEIAVLAKIKKENIVTLEDIYESTHYLYVMOLVSGGELFDRLERGVYTEKA 141  
 XX OY 121 SLVIOQVLSAVKYLYENGIVHRDKPENLLYLPENSKINITFDGLSKNEONGIMSTAC 180  
 XX DB 142 SLVIOQVLSAVKYLYENGIVHRDKPENLLYLPENSKINITFDGLSKNEONGIMSTAC 201  
 XX

```

OY 181 GTPGYAPVLAQKPYSKAYDCWSIGVITILLCGYPPFYBETESKLFEKIKEGYEFES 240
DB 202 GTPGYAPVLAQKPYSKAYDCWSIGVITILLCGYPPFYBETESKLFEKIKEGYEFES 261
OY 241 PFNDIISSEKDFICHLEKOPNERITCEKALSHPWIDONTALHROIYPSYSLOIQKPA 300
DB 262 PFNDIISSEKDFICHLEKOPNERITCEKALSHPWIDONTALHROIYPSYSLOIQKPA 321
OY 301 KSKWROAFNAAYVHHMKLHMLHSPGYRPEVENPPEPETOASSETSRPSPPEITITAPV 360
DB 322 KSKWROAFNAAYVHHMKLHMLHSPGYRPEVENPPEPETOASSETSRPSPPEITITAPV 381
OY 361 LDHSAVLPALTLQPCOHGRPTAPGGRSLNCLVNGSLHISSSLVPHQCSLAAGPCCCS 420
DB 382 LDHSAVLPALTLQPCOHGRPTAPGGRSLNCLVNGSLHISSSLVPHQCSLAAGPCCCS 441
OY 421 SCLNIGSGESSYCSPTLLKANKKONPKSEVNVYPVKAAGSSSHCRAGOTGVCLIM 476
DB 442 SCLNIGSGESSYCSPTLLKANKKONPKSEVNVYPVKAAGSSSHCRAGOTGVCLIM 497

```

OS Homo sapiens.  
XX  
PN WO200153312-A1.  
XX  
PD 26-JUL-2001.  
XX  
PF 26-DEC-2000; 2000WO-US34263.  
XX  
PR 21-JAN-2000; 2000US-0488725.  
PR 25-APR-2000; 2000US-0552317.  
PR 09-JUL-2000; 2000US-0398042.  
PR 19-JUL-2000; 2000US-0620312.  
PR 03-AUG-2000; 2000US-0653450.  
PR 14-SEP-2000; 2000US-0662191.  
PR 19-OCT-2000; 2000US-0853036.  
PR 29-NOV-2000; 2000US-0727344.  
XX  
PA (HYSE-) HYSEQ INC.

XX  
XX  
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;  
PI Wang J, Wang Z, Mehrman T, Xu C, Xue AJ, Yang Y, Zhang J;  
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;  
XX  
DR WPI: 2001-442253/47.  
DR P-PSDB: AAM41547.  
XX  
XX  
PT Novel nucleic acids and polypeptides, useful for treating disorders  
PT such as central nervous system injuries -  
XX  
PS Claim 1: SEQ ID NO 4692; 10078pp; English.

XX  
CC The invention relates to human nucleic acids (AA157798-AA161369) and  
CC the encoded polypeptides (AAM38642-AAM42213) with neurotropic,  
CC immunosuppressant and cytostatic activity. The polynucleotides are useful  
CC in gene therapy. A composition containing a polypeptide or polynucleotide  
CC of the invention may be used to treat diseases of the peripheral nervous  
CC system, such as peripheral nervous injuries, peripheral neuropathy and  
CC localised neuropathies and central nervous system diseases, such as  
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
CC utilisation of the activities such as: Immune system suppression,  
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic  
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,  
CC assays for receptor activity, arthritis and inflammation, leukaemia and  
CC C.N.S disorders.  
CC Note: the sequence data for this patent did not form part of the printed  
CC specification.  
XX  
SQ Sequence 1956 BP: 474 A: 559 C: 508 G: 414 T: 1 other:

Query Match 68.9%; Score 1687; DB 22; Length 1956;  
Best Local Similarity 99.9%; Pred. No. 0;  
Matches 1787; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 12 CTCAGCAGGATTCCTCCGAGTCCCTGGCATCTCTCAGAGCTTCAACTCTGGAGGCAAT 71  
DB 7 CTCAGCAGGATTCCTCCGAGTCCCTGGCATCTCTCAGAGCTTCAACTCTGGAGGCAAT 66  
QY 72 GGGTCGAAAGGAGAGATGATGCTGGATTCCTGGAGAAACAGACCCACACATCCGGAA 131  
DB 67 GGGTCGAAAGGAGAGATGATGCTGGATTCCTGGAGAAACAGACCCACACATCCGGAA 126  
QY 132 AACCTTCATTTTATGGAAGTGGTGGGATCAGGAGCTTCTCAGAGAGTTTCTCGTGCAA 191  
DB 127 AACCTTCATTTTATGGAAGTGGTGGGATCAGGAGCTTCTCAGAGAGTTTCTCGTGCAA 186  
QY 192 CCAGAGCTGCTCCGAGCTCTTCTGCTGAGTGATCAGAGCTTCAAGAGTACCTGCTCCG 251  
DB 187 CCAGAGCTGCTCCGAGCTCTTCTGCTGAGTGATCAGAGCTTCAAGAGTACCTGCTCCG 246  
QY 252 GGACAGCAGCTTGGAGATGATGCTGCTGTTGAAAGATCAGAGCTTCAAGAGTACCTG 311  
DB 247 GGACAGCAGCTTGGAGATGATGCTGCTGTTGAAAGATCAGAGCTTCAAGAGTACCTG 306

RESULT 2  
AA160703  
ID AA160703 standard; cDNA; 1956 BP.  
XX  
AC AA160703;  
XX  
DT 22-OCT-2001 (first entry)  
XX  
DE Human polynucleotide SEQ ID NO 4692.  
XX  
XX Human: neurotropic; immunosuppressant; cytostatic; gene therapy; cancer;  
XX peripheral nervous system; neuropathy; central nervous system; CNS;  
XX Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
XX amyotrophic lateral sclerosis; Shy Drager Syndrome; chemotactic;  
XX chemokinetic; thrombolytic; drug screening; arthritis; inflammation;  
XX leukaemia; ss.  
XX

OY 312 GACCTGGAGGACATCTATGAGAGCACCACCACTACTACTGCTGATGCGCTTGTTC 371  
DB 307 GACCTGGAGGACATCTATGAGAGCACCACCACTACTACTGCTGATGCGCTTGTTC 366  
OY 372 TGGTGGGAGCTCTTGGACGGATCTGGAGCGGGGTGTCTACAGAGAGAGAGTGGCAG 431  
DB 367 TGGTGGGAGCTCTTGGACGGATCTGGAGCGGGGTGTCTACAGAGAGAGATGGCAG 426  
OY 432 TCTGGTGAATCCAGCAGAGCTCTGTCCGCAATGAAATACCTACATGAGAAATGGCATCTGCA 491  
DB 427 TCTGGTGAATCCAGCAGAGCTCTGTCCGCAATGAAATACCTACATGAGAAATGGCATCTGCA 486  
OY 492 CAGAGACTTAAAGCCGAAACCTGCTTTACCTTACCTGCTGAAAGAGACTCTAAGATCAT 551  
DB 487 CAGAGACTTAAAGCCGAAACCTGCTTTACCTTACCTGCTGAAAGAGACTCTAAGATCAT 546  
OY 552 GATCAGTACTTGGTCTGTCGCAAGATGGAACAGATGGGATCATGTCCAGTCCCTGTGG 611  
DB 547 GATCAGTACTTGGTCTGTCGCAAGATGGAACAGATGGGATCATGTCCAGTCCCTGTGG 606  
OY 612 GACCCAGGCTACGTGGCTCCAGAGTCTGGCCAGAAACCTTACAGCAAGGCTGTGA 671  
DB 607 GACCCAGGCTACGTGGCTCCAGAGTCTGGCCAGAAACCTTACAGCAAGGCTGTGA 666  
OY 672 TTGCTGGTCCATCGGCGTCACTACCTACATATGCTGTGGATACCCCGCTTCTATCA 731  
DB 667 TTGCTGGTCCATCGGCGTCACTACCTACATATGCTGTGGATACCCCGCTTCTATCA 726  
OY 732 AGAAGCGGAGTCTAAGCTTTTCGAGAGATCAAGGAGGCTACTATGATTTGAGTCTCC 791  
DB 727 AGAAGCGGAGTCTAAGCTTTTCGAGAGATCAAGGAGGCTACTATGATTTGAGTCTCC 786  
OY 792 ATTCTGGGATGACATTTCTGAGTCAAGCCAGGAGCTTTATTTGCCACTTGTCTGAGAAGA 851  
DB 787 ATTCTGGGATGACATTTCTGAGTCAAGCCAGGAGCTTTATTTGCCACTTGTCTGAGAAGA 846  
OY 852 TCGGACGAGCGGTACACCTGTGAGAGGCTTGGATCATCCCTGCTGNTTGGAGGAACAC 911  
DB 847 TCGGACGAGCGGTACACCTGTGAGAGGCTTGGATCATCCCTGCTGNTTGGAGGAACAC 906  
OY 912 GGCCCTCAGCGGAGCATCTACCCATCAGTCAAGCTCCAGTCCAGTCCAGAGAGACTTGTCTAA 971  
DB 907 AGCCCTCCAGCGGAGCATCTACCCATCAGTCAAGCTCCAGTCCAGTCCAGAGAGACTTGTCTAA 966  
OY 972 GAGCAAGTGGAGGCAAGCTTCAAGCCAGCAGCTGTGGTGCACCAATGAGGAAGCTACA 1031  
DB 967 GAGCAAGTGGAGGCAAGCTTCAAGCCAGCAGCTGTGGTGCACCAATGAGGAAGCTACA 1026  
OY 1032 CATGAACCTGCACAGCGCGGCGTCCGCCAGAGGTGGAGAGAGGCGGCTGAAACTCA 1091  
DB 1027 CATGAACCTGCACAGCGCGGCGTCCGCCAGAGGTGGAGAGAGGCGGCTGAAACTCA 1086  
OY 1092 AGCTCAGAAACCTCTAGAGCCAGCTCCCTGAGATCACCCTCAGGAGGAGCCTGTCT 1151  
DB 1087 AGCTCAGAAACCTCTAGAGCCAGCTCCCTGAGATCACCCTCAGGAGGAGCCTGTCT 1146  
OY 1152 GGAGCAAGTGTAGCACTCTCCCTGCTGAGCCCAATTAACCTGCGCAAGATGGCGCGCGGCC 1211  
DB 1147 GGAGCAAGTGTAGCACTCTCCCTGCTGAGCCCAATTAACCTGCGCAAGATGGCGCGCGGCC 1206  
OY 1212 CAGTGGCCCTGTGGAGGCTCCCTCAACTGCTGGTCAATGGCTCCCTCCACATCAGCAG 1271  
DB 1207 CAGTGGCCCTGTGGAGGCTCCCTCAACTGCTGGTCAATGGCTCCCTCCACATCAGCAG 1266  
OY 1272 CAGCTGGTGGCCATGATCAGGGGTCTCCCTGGCGCGGCGGCTGCTGCTGCTCCAG 1331  
DB 1267 CAGCTGGTGGCCATGATCAGGGGTCTCCCTGGCGCGGCGGCTGCTGCTGCTCCAG 1326  
OY 1332 CTGCTCGAACAATTGGGAGCAAGGAAAGTCTCTCTACTGCTGTGAGGCGCACACTCTCAA 1391  
DB 1327 CTGCTCGAACAATTGGGAGCAAGGAAAGTCTCTCTACTGCTGTGAGGCGCACACTCTCAA 1386

OY 1392 AAAGGCCAAACAAAACAGAACTTCAAGTCCGAGGTCACTGCTACCACTTAAGCCAGTGG 1451  
DB 1387 AAAGGCCAAACAAAACAGAACTTCAAGTCCGAGGTCACTGCTACCACTTAAGCCAGTGG 1446  
OY 1452 CAGCTCCGACTGCGGGCAGGGGAGACTGGAGTCTGCTCATATGATGCTGNTTCTGGAGCC 1511  
DB 1447 CAGCTCCGACTGCGGGCAGGGGAGACTGGAGTCTGCTCATATGATGCTGNTTCTGGAGCC 1506  
OY 1512 TGTGCTTATGTCACTGCAATTTTCAGGAGACATATTCAACTCTCTGCTTTCACAACT 1571  
DB 1507 TGTGCTTATGTCACTGCAATTTTCAGGAGACATATTCAACTCTCTGCTTTCACAACT 1566  
OY 1572 GGTGCTTATCCGCGCAGAGGAGGAGGAGCAAGTGGAGAGGCTTATGAGGAGCAG 1631  
DB 1567 GGTGCTTATCCGCGCAGAGGAGGAGGAGCAAGTGGAGAGGCTTATGAGGAGCAG 1626  
OY 1632 TTTCTGGCCAGAGGAGCAGGCTGCTGCCAGCGGGGAGGCGCTCATAGGAGGCGCCAGGA 1691  
DB 1627 TTTCTGGCCAGAGGAGCAGGCTGCTGCCAGCGGGGAGGCGCTCATAGGAGGCGCCAGGA 1686  
OY 1692 GGGAGCCCGCAAGCCGTAGAAGCCTTGTGAGCTGTGAGCAGGAGAGCGGTGCGCCACCA 1751  
DB 1687 GGGAGCCCGCAAGCCGTAGAAGCCTTGTGAGCTGTGAGCAGGAGAGCGGTGCGCCACCA 1746  
OY 1752 GCTTCCAGAGTCTCTGCTGACCTGCTCTATGCGCCACACACCTACGCTG 1800  
DB 1747 GCTTCCAGAGTCTCTGCTGACCTGCTCTATGCGCCACACACCTACGCTG 1795